Sol Shenker

This study identifies Regnase-1 and SOCS1 dual-inactivation as a strategy to enhance anti-tumor functionality of CD8+ T cells by rewiring their differentiation and effector state.

This paper describes a gene-engineered B Cell Medicine (BE-101) that produces sustained active factor IX for hemophilia B therapy, showing durable and redosable effects in mice.

This study predicts HRD in 1,332 cancer and 84 non-cancer cell lines using CHORD and HRDsum, finding BRCA1/2 mutations and epigenetic silencing as key predictors.

This study uses CRISPR/Cas9 screens to identify SOCS1 as a target for enhancing T cell therapy, leading to the development of an engineered TIL therapy with improved anti-tumor function.

CrossBrowse enables visualization of cross-species genomic datasets, revealing insights into functional element conservation and divergence across species.